MedTrace Logo

Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia

NCT00333177 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2020-03-26

Study results available
· View outcomes & findings →

Summary

This study will determine the effectiveness of various combinations of psychosocial therapy and risperidone treatment in improving work or school performance in people with first-episode schizophrenia.

Conditions

Interventions

BEHAVIORAL

Cognitive remediation training (CT)

Cognitive remediation training includes computerized cognitive training plus learning skills group.

BEHAVIORAL

Healthy behavior training (HBT)

Healthy behavior training includes group skills training in nutrition, exercise, and relaxation.

DRUG

Risperidone, administered orally (Oral Ris)

Oral risperidone at dosage judged optimal by treating psychiatrist

DRUG

Risperidone, administered via injection (RLAI)

Risperidone in injectable form every 2 weeks, starting with 25 mg and adjusted as needed

Sponsors & Collaborators

Principal Investigators

  • Keith H. Nuechterlein, PhD · University of California, Los Angeles, Department of Psychiatry and Biobehavioral Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2013-01-31
Completion
2013-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00333177 on ClinicalTrials.gov